Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.
馬薩諸塞州列剋星敦，2024年6月13日（GLOBE NEWSWIRE）——致力於推進神經遺傳學藥物發展的生物技術公司Voyager Therapeutics, Inc.（納斯達克股票代碼：VYGR）今天宣佈，該公司將在美國東部時間2024年6月20日下午1點35分參加TD Cowen遺傳醫學和RNA峯會以及6月27日H.C. Wainwright第五屆年度神經展望虛擬會議的爐邊談話。2024 年，美國東部時間上午 7:00
Webcasts of the presentations may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company's website for at least 30 days.
演示文稿的網絡直播可從Voyager網站的 “投資者” 部分訪問，網址爲 ir.voyagertherapeutics.com。網絡廣播的重播將在公司網站上存檔至少30天。
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
關於旅行者療法
Voyager Therapeutics, Inc.（納斯達克股票代碼：VYGR）是一家生物技術公司，致力於利用人類遺傳學的力量來改變並最終治癒神經系統疾病。我們的研發項目包括針對阿爾茨海默氏病、肌萎縮性側索硬化 (ALS)、帕金森氏病和其他多種中樞神經系統疾病的項目。我們的許多項目都源自我們的 TRACER AAV 衣殼發現平台，我們使用該平台生成新的衣殼和鑑定相關受體，從而有可能在靜脈注射後通過基因藥物實現高大腦穿透率。我們的一些項目是全資擁有的，還有一些正在與包括Alexion、阿斯利康罕見病、諾華製藥股份公司、Neurocrine Biosciences, Inc.和Sangamo Therapeutics, Inc.在內的合作伙伴一起推進。欲了解更多信息，請訪問 www.voyagerterapeutics.com。
Voyager Therapeutics is a registered trademark, and TRACER is a trademark, of Voyager Therapeutics, Inc.
旅行者療法 是 Voyager Therapeutics, Inc. 的註冊商標，TRACER 是商標。
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
聯繫人
特里斯塔·莫里森，NACD.DC， tmorrison@vygr.com
投資者：亞當·貝羅博士 abero@kendallir.com
媒體：布魯克·申金， brooke@scientpr.com
Source: Voyager Therapeutics, Inc.
資料來源：Voyager Therapeutics, Inc.